• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[一株产生CA125的人卵巢透明细胞癌细胞系的建立与鉴定]

[Establishment and characterization of a CA125-producing human ovarian clear cell carcinoma cell line].

作者信息

Sasa H, Ishii K, Hirata J, Kikuchi Y, Nagata I, Kawai T, Senoo A, Sugita M, Sugishita T, Tenjin Y

机构信息

Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan.

出版信息

Hum Cell. 1993 Dec;6(4):279-86.

PMID:8148309
Abstract

A human ovarian cancer cell line designated "KK" was established from ascites of a patient with ovarian clear cell carcinoma. This cell line was grown for more than 2 years and over 140 passages in medium RPMI1640 containing 10% FCS. Doubling time of this cell line at passage 70 was approximately 4 days and saturation density was 1.1 x 10(5)/cm2. Plating efficiency was approximately 23%. Chromosome analysis revealed aneuploidy with a model number of 67. PAS-positive substances were present in the cytoplasm. CA125 and SLX were detected in both the original tumor and the cultured cells. This cell line is less sensitive to cisplatin than KF cells and IC50 was 0.95 microM.

摘要

一种名为“KK”的人卵巢癌细胞系是从一名卵巢透明细胞癌患者的腹水中建立的。该细胞系在含有10%胎牛血清的RPMI1640培养基中培养了2年多,传代超过140次。该细胞系在第70代时的倍增时间约为4天,饱和密度为1.1×10(5)/cm2。接种效率约为23%。染色体分析显示为非整倍体,众数为67。细胞质中存在PAS阳性物质。在原发肿瘤和培养细胞中均检测到CA125和SLX。该细胞系对顺铂的敏感性低于KF细胞,IC50为0.95微摩尔。

相似文献

1
[Establishment and characterization of a CA125-producing human ovarian clear cell carcinoma cell line].[一株产生CA125的人卵巢透明细胞癌细胞系的建立与鉴定]
Hum Cell. 1993 Dec;6(4):279-86.
2
[Establishment of a cisplatin-resistant human ovarian cancer cell line].[顺铂耐药人卵巢癌细胞系的建立]
Hum Cell. 1993 Jun;6(2):106-13.
3
Establishment and characterization of human ovarian clear cell adenocarcinoma cell line (SMOV-2), and its cytotoxity by anticancer agents.人卵巢透明细胞腺癌细胞系(SMOV-2)的建立与鉴定及其对抗癌药物的细胞毒性
Hum Cell. 1999 Sep;12(3):139-48.
4
Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.从具有不同特性的转移病灶中建立并鉴定两个人类卵巢透明细胞腺癌系。
Gynecol Oncol. 1995 Apr;57(1):33-46. doi: 10.1006/gyno.1995.1097.
5
[Establishment of a cell line from human ovarian cancer (undifferentiated carcinoma of FIGO classification) and analysis of its cell-biological characteristics and sensitivity to anticancer drugs].[人卵巢癌(国际妇产科联盟分类的未分化癌)细胞系的建立及其细胞生物学特性和对抗癌药物敏感性的分析]
Nihon Sanka Fujinka Gakkai Zasshi. 1986 Oct;38(10):1747-53.
6
Characterization of a human ovarian carcinoma cell line: UCI 101.一种人卵巢癌细胞系UCI 101的特性分析。
Gynecol Oncol. 1993 Feb;48(2):203-9. doi: 10.1006/gyno.1993.1034.
7
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma.源自人卵巢浆液性囊腺癌的新建立细胞系HUOA的特性分析
Nihon Sanka Fujinka Gakkai Zasshi. 1987 May;39(5):831-6.
8
[Establishment and characterization of a human ovarian adenocarcinoma cell line OC-8611].[人卵巢腺癌细胞系OC-8611的建立与鉴定]
Zhonghua Zhong Liu Za Zhi. 1989 Nov;11(6):416-8.
9
[Establishment and characterization of a human scirrhus type gastric cancer cell line, GCIY, producing CA19-9].[人黏液腺癌型胃癌细胞系GCIY的建立及其产生CA19-9的特性研究]
Hum Cell. 1991 Mar;4(1):71-5.
10
Establishment and characterization of a new human cell-line (AMOC-2) derived from a serous adenocarcinoma of ovary.源自卵巢浆液性腺癌的新型人类细胞系(AMOC-2)的建立与鉴定
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Jul;41(7):888-94.

引用本文的文献

1
Nicotinamide N-methyltransferase enhances paclitaxel resistance in ovarian clear cell carcinoma.烟酰胺N-甲基转移酶增强卵巢透明细胞癌对紫杉醇的耐药性。
Hum Cell. 2025 Aug 25;38(5):151. doi: 10.1007/s13577-025-01282-z.
2
Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis.伴有子宫内膜异位症的卵巢透明细胞癌的转录组分析。
Front Endocrinol (Lausanne). 2023 Aug 9;14:1162786. doi: 10.3389/fendo.2023.1162786. eCollection 2023.
3
JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.JAK2/STAT3通路作为卵巢癌的治疗靶点
Oncol Lett. 2018 Apr;15(4):5772-5780. doi: 10.3892/ol.2018.8028. Epub 2018 Feb 12.
4
Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.抑制自噬蛋白LC3A作为卵巢透明细胞癌的治疗靶点。
J Gynecol Oncol. 2017 May;28(3):e33. doi: 10.3802/jgo.2017.28.e33. Epub 2017 Feb 13.
5
X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.X 染色体连锁凋亡抑制剂作为卵巢透明细胞癌化疗耐药的关键因素。
Br J Cancer. 2014 Jun 10;110(12):2881-6. doi: 10.1038/bjc.2014.255. Epub 2014 May 22.
6
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.透明细胞卵巢癌中mir-100与FRAP1/mTOR之间的联系。
Mol Endocrinol. 2010 Feb;24(2):447-63. doi: 10.1210/me.2009-0295. Epub 2010 Jan 15.
7
HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.HER2在卵巢透明细胞腺癌中经常过度表达:使用抗HER2重组单克隆抗体曲妥珠单抗的可能新治疗方式。
Jpn J Cancer Res. 2002 Nov;93(11):1250-7. doi: 10.1111/j.1349-7006.2002.tb01231.x.